Investor Relations

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

Corporate Presentation

Corporate Presentation

Download Corporate Presentation

Stock Information

Latest Financial Results

Q3 2019

Quarter Ended Sep 30, 2019

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018

View Filing

Investor Contact Information

Company

CollPlant Biotechnologies Ltd.
4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Corporate ProfileĀ®
Laurel Moody
1185 Avenue of the Americas 3rd Floor
New York, NY 10036
T: +1 212 931 8787 Ext 101

Transfer Agent

The Bank of New York Mellon
Depositary Receipts Division - Global Client Solutions
Arlene C. Villareal
Vice President
101 Barclay Street, 22W
New York, NY 10286
T: 212-815-8162
Arlene.villareal@bnymellon.com

® 2020 CollPlant Biotechnologies Ltd. All rights reserved. Version: CPW 02-20

Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.